But when it came to the secondary endpoint of interim overall survival (OS), the ITM-11 cohort reached 63.4 months while the everolimus group was not far behind at 58.7 months. This gap was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback